Pfizer inks COPD promo deal with Novartis in U.K.; Roche chair says no big mergers;

@FiercePharma: Tops on FPMarketing Weds: Can Sanofi/Regeneron's new data one-up Amgen in megablockbuster PCSK9 field? Article | Follow @FiercePharma

@EricPFierce: Agents in EU seize €10M worth of counterfeit drugs, as well as cash and luxury cars, arrest a dozen. FiercePharmaManufacturing story | Follow @EricPFierce

@CarlyHFierce: ICYMI yesterday: Sanofi's dengue shot ups serotype 2 protection rate in final trial. FierceVaccines story | Follow @CarlyHFierce

> Pfizer ($PFE) has signed on to promote two of Novartis' ($NVS) lung drugs, Seebri and Ultibro, in the U.K. Report

> Roche ($RHHBY) Chairman Christoph Franz says the company has ruled out "double-digit billion" deals, but is still open to smaller transactions. Report

> Some drugmakers have bowed out of supplying the Indian government with HIV-fighting drugs because of delayed payments, triggering a shortage. Report

> Fresenius Kabi Oncology, the Indian arm of Germany's Fresenius Kabi, withdrew its petitions asking Indian patent officials to pull IP protections on Pfizer's ($PFE) cancer meds Xalkori and Inlyta. Report

> The Chinese drugmaker Tasly Holding cut the ribbon on its North American operations Wednesday, as part of its plans to expand internationally. Report

> Novo Nordisk ($NVO) cut 63 jobs in Seattle as part of its plans to exit inflammatory drug R&D. Report

Medical Device News

@FierceMedDev: Researchers develop self-powered pacemaker system based on automatic wristwatch. Article | Follow @FierceMedDev

@VarunSaxena2: Per Capita Medicare Spending Is Actually Falling. More from the NYT | Follow @VarunSaxena2

@MichaelGFierce: Artificial virus promises effective drug delivery and gene therapy. FierceDrugDelivery story | Follow @MichaelGFierce

@EmilyWFierce: Fingerprint scanning system could help track children's vaccinations in developing countries. More from MIT Technology Review | Follow @EmilyWFierce

> AdvaMed says FDA proposed rule would result in more PMAs, device reclassifications. More

> Four lessons about the orthopedics industry from the CEO of group purchasing organization Amerinet. Editor's corner

> Propeller Health gets $14.5M Series B for smart inhaler, app combo. Article

Biotech News

@FierceBiotech: ICYMI: $GSK's new Boston collaboration chief goes 'anti-pharma' as he prowls for partners. Article | Follow @FierceBiotech

@JohnCFierce: In diabetes, everybody is trying to beat everybody on next steps. Which is why Afrezza continues to stand out as a lonely effort. | Follow @JohnCFierce

@DamianFierce: $KMDA won't let a little thing like missing its endpoints in PhII/III derail a regulatory filing. More | Follow @DamianFierce

@EmilyMFierce: FDA rushes J&J, NewLink Ebola vaccines to clinical trials. More | Follow @EmilyMFierce

> Edison's orphan drug misses the mark in Phase II. Story

> Lilly claims another head-to-head victory over Lantus in PhIII diabetes showdown. Report

> J&J teams with Bavarian Nordic on an emergency Ebola vaccine program. More

Vaccines News

> FDA rushes J&J, NewLink Genetics Ebola vaccines to clinical trials. Article

> Study: Old HIV pediatric vaccines might provide protection after all. Item

> Amid Bexsero negotiations, Novartis medical director slams U.K. vaccine assessment system. More

> Sanofi's dengue shot ups serotype 2 protection rate in final trial. Story

> Amgen submits melanoma-fighter T-Vec to EMA on the heels of its FDA filing. Report

Pharma Manufacturing News

> Theratechnologies returns HIV product Egrifta to U.S. Item

> Wockhardt expects to resolve most FDA concerns within the year. Report

> China sweeps up gang that made and sold 90M toxic capsules. More

> Actavis production not meeting demand for new version of Alzheimer's drug. Story

> Xellia lays out $100M expansion plan for new U.S. facility. Article

And Finally... CVS Health, formerly CVS Caremark, has decided to replace tobacco sales with a smoking-cessation campaign. Report

Suggested Articles

Stephen Hahn, an oncologist who served as the chief medical officer for the MD Anderson Cancer Center, has secured Senate confirmation as FDA head.

As BMS searches for bright spots in its Opdivo-chemo combo fail from June, it’s zeroing in on squamous lung cancer patients who seemed to benefit.

The FDA's ad watchdog served its most serious violation to Alkermes Wednesday—and it took the unusual step of announcing that violation to the world.